[Podcast] The Conflict Between QALYs for Drug Value and Patient Advocacy Groups

In the latest episode of the Relentless Health Value podcast, Stacey Richter interviews Memorial Sloan Kettering’s Anna Kaltenboeck about how the Quality-Adjusted Life Year (QALY) is used to recognize which treatments are best at improving patients’ lives, and to help determine a price that is fairly and proportionately scaled to those improvements. Ms. Kaltenboeck explained how the endgame isn’t just fair pricing, but the reciprocation of fair access. Listen here.